AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$OBIO

Hochman David P purchased $25K of OBIO (indirect holdings)

Hochman David P (See Remarks) purchased 5,000 indirectly-held shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 on 2026-11-09.

Original reporting
SEC EDGAR · Hochman David P
Published Nov 9, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OBIO
Neutral
high confidence
Mentioned
$OBIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OBIONeutralLow
01

Why it matters

The disclosed purchase is small and unlikely to move the stock significantly.

02

Market read

A modest insider buy that may provide slight positive sentiment but limited trading relevance.

03

What to watch

Potential upcoming clinical data or partnership not disclosed could be driving the purchase.

Relevance 4/10Novelty 3/10Timing: after-hours filing today

Background

Form 4 filing reports insider transactions for public companies.

Company-level read

Ticker impact

$OBIONeutralHigh confidence
Context

Officer/director David P. Hochman bought 5,000 shares at $5 each, increasing his stake to 437,916 shares.

Expected impact

modest upward pressure as market prices in insider buying

Evidence & confidence

Form 4 is primary source; purchase amount is low relative to float, limiting market impact.

Market effects

Sector

Minimal effect on biotech sector; insider activity is routine.

Regional

No regional impact.

Global

Limited to investors tracking OBIO.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Company
    Orchestra BioMed Holdings, Inc.

    Biotech firm listed on NASDAQ under ticker OBIO.

  • Person
    David P. Hochman

    Officer and director of OBIO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OBIO insider trading history →

Related articles

$OBIOMed

H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment

H.C. Wainwright reiterated a Buy rating and $10.00 price target for Orchestra BioMed (OBIO) after its hypertension trial completed enrollment. The stock trades at $5.95, with a 119.56% return over the past year. The BACKBEAT trial, conducted with Medtronic, aims to treat uncontrolled hypertension in pacemaker patients. Orchestra plans to submit results for regulatory review in 2027. BTIG also upgraded OBIO to Buy with a $10 target.

investing.com